{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010277","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.663639+00:00","generated_at":"2026-06-14T18:07:26.249221+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"AYTU Biopharma stockholders approve 2023 equity incentive plan and elect all director nominees","bullets":["All five director nominees elected; For votes ranged 673,707–685,411, Withheld 304,133–315,837.","2023 Equity Incentive Plan approved: 632,357 For, 352,359 Against, 4,828 Abstain; 952,620 broker non-votes.","Ratification of Grant Thornton as independent auditor approved: 1,754,922 For, 132,135 Against, 55,107 Abstain.","Advisory vote on executive compensation approved (non-binding): 587,253 For, 383,698 Against, 18,593 Abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010277","json":"https://secwatch.observer/filing/0001558370-23-010277.json","markdown":"https://secwatch.observer/filing/0001558370-23-010277.md","text":"https://secwatch.observer/filing/0001558370-23-010277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/0001558370-23-010277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/aytu-20230518x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:07:26.249221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0c8172224c2a59b9790933f8310246aefb8aefa","claim":"AYTU BIOPHARMA, INC shareholders approved Advisory vote on executive compensation at the 2023-05-18 meeting.","evidence_excerpt":"The advisory vote on executive compensation was approved with 587,253 votes in favor, 383,698 votes against and 18,593 abstentions. There were 952,620 broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/0001558370-23-010277-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"cc2a6a7f03673312a550aee9a2b4240b06b4ea97","claim":"AYTU BIOPHARMA, INC shareholders approved Election of five directors at the 2023-05-18 meeting.","evidence_excerpt":"Our stockholders elected five members to our board of directors as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/0001558370-23-010277-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"ea68aaa48900d3bd00bab6f364c853ac9287eb4e","claim":"AYTU BIOPHARMA, INC shareholders approved Ratification of the appointment of Grant Thornton, LLC as independent registered public accounting firm at the 2023-05-18 meeting.","evidence_excerpt":"The ratification of the appointment of Grant Thornton, LLC as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2023 was approved with 1,754,922 votes in favor, 132,135 votes against and 55,107 abstentions.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/0001558370-23-010277-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"f6a9d6c6228436be5927fee48acad32ae4782a82","claim":"AYTU BIOPHARMA, INC shareholders approved Approval of the 2023 Equity Incentive Plan at the 2023-05-18 meeting.","evidence_excerpt":"The approval of a new equity incentive plan for certain officers, directors, employees and other key personnel, the “2023 Equity Incentive Plan” was approved with 632,357 votes in favor, 352,359 votes against, and 4,828 abstentions. There were 952,620 broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/0001558370-23-010277-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}